Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04739072

Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study

Sponsor: M.D. Anderson Cancer Center

View on ClinicalTrials.gov

Summary

This study investigates if circulating tumor DNA (ctDNA) and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread. Tumors shed DNA and other cancer related chemicals into the blood that can be identified and studied further to provide information about the cancer. Information gathered from this study may help researchers better understand if ctDNA found in the blood can predict whether colorectal cancer may come back or spread.

Official title: Minimal Residual Disease Assessment in Colorectal Cancer (MiRDA-C)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

1000

Start Date

2019-11-22

Completion Date

2025-12-31

Last Updated

2025-11-13

Healthy Volunteers

No

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of blood and tissue samples

OTHER

Electronic Health Record Review

Review of medical records

Locations (10)

Banner - MD Anderson Cancer Center

Gilbert, Arizona, United States

Baptist- MD Anderson Cancer Center

Jacksonville, Florida, United States

The Queen's Medical Center

Honolulu, Hawaii, United States

St. Luke's Cancer Institute

Boise, Idaho, United States

Cooper Hospital UNIV MED CTR.

Camden, New Jersey, United States

UT Southwestern/Simmons Cancer Center-Dallas

Dallas, Texas, United States

Houston Methodist Cancer Center

Houston, Texas, United States

M D Anderson Cancer Center

Houston, Texas, United States

UT Health San Antonio MD Anderson Cancer Center

San Antonio, Texas, United States

Baylor Scott & White Research Institute

Temple, Texas, United States